Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Depreciation & Amortization (CF) (2021 - 2025)

Verrica Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 5 years, most recently at $21807.0 for Q3 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $21807.0 for Q3 2025, down 78.19% from a year ago — trailing twelve months through Dec 2025 was $118807.0 (down 64.85% YoY), and the annual figure for FY2025 was $100000.0, down 66.67%.
  • Depreciation & Amortization (CF) for Q3 2025 was $21807.0 at Verrica Pharmaceuticals, down from $45000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for VRCA hit a ceiling of $142000.0 in Q4 2021 and a floor of $11000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $100000.0 (2023), compared with a mean of $81884.6.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 790.91% in 2022 and later tumbled 88.12% in 2024.
  • Verrica Pharmaceuticals' Depreciation & Amortization (CF) stood at $142000.0 in 2021, then decreased by 7.75% to $131000.0 in 2022, then dropped by 22.9% to $101000.0 in 2023, then tumbled by 88.12% to $12000.0 in 2024, then soared by 81.73% to $21807.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $21807.0 (Q3 2025), $45000.0 (Q2 2025), and $52000.0 (Q1 2025) per Business Quant data.